Last reviewed · How we verify

NCT02653625

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Completed Phase 2 Results posted Last updated 1 October 2018
What this trial tests

Phase 2 trial testing Cenicriviroc 150 mg in Primary Sclerosing Cholangitis in 24 participants. Completed in 31 August 2017.

Timeline
14 March 2016
Primary endpoint
31 August 2017
31 August 2017

Quick facts

Lead sponsorTobira Therapeutics, Inc.
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment24
Start date14 March 2016
Primary completion31 August 2017
Estimated completion31 August 2017
Sites9 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

Tobira Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Primary Sclerosing Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP) Primary · Baseline (Day 1) to Week 24

ALP was used as a primary surrogate marker for measuring Primary Sclerosing Cholangitis disease. The percent change from Baseline was defined as 100\*(value at each visit - Baseline value)/Baseline value. The Baseline value was defined as the last non-missing value on or before the Baseline visit (Day 1). A negative percentage change from baseline indicates an improvement.

GroupValue95% CI
Cenicriviroc 150 mg-4.5± 34.84
Percentage of Participants Who Normalized ALP at Week 24 Secondary · Week 24

ALP was used as a primary surrogate marker for measuring Primary Sclerosing Cholangitis disease. Normalization was defined as ALP values outside of the central laboratory reference range at baseline, but within the central laboratory reference range at Week 24.

GroupValue95% CI
Cenicriviroc 150 mg0.00.83 – 1.00
Percentage of Participants Who Achieved Serum ALP of Less Than 1.5 Times Upper Limit of Normal (ULN) in Serum ALP at Week 24 Secondary · Week 24

ALP was used as a primary surrogate marker for measuring Primary Sclerosing Cholangitis disease. The upper limit of normal ALP was defined according to the central laboratory reference ranges.

GroupValue95% CI
Cenicriviroc 150 mg100.68 – 0.98
Percentage of Participants Who Achieved a 50% Decrease in ALP at Week 24 Secondary · Week 24

ALP was used as a primary surrogate marker for measuring Primary Sclerosing Cholangitis disease.

GroupValue95% CI
Cenicriviroc 150 mg0.00.83 – 1.00
Percentage of Participants With a Treatment-emergent Adverse Event (TEAE) Secondary · Baseline (Day 1) to Week 24

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, regardless of whether related to the medicinal (investigational) product. A TEAE was defined as an AE with an onset that occurred after receiving treatment.

GroupValue95% CI
Cenicriviroc 150 mg83.3
Percentage of Participants Who Discontinued Due to a TEAE Secondary · Baseline (Day 1) to Week 24

An adverse event was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, regardless of whether related to the medicinal (investigational) product. A TEAE was defined as an AE with an onset that occurred after receiving treatment.

GroupValue95% CI
Cenicriviroc 150 mg8.3

Adverse events — posted to ClinicalTrials.gov

Time frame: From Baseline (Day 1) to Week 24. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cenicriviroc 150 mg
Serious: 1/24 (4%)
Deaths: 0/24

Serious adverse events (1 terms)

ReactionSystemCenicriviroc 150 mg
Gallbladder polypHepatobiliary disorders
Other adverse events (13 terms — click to expand)

ReactionSystemCenicriviroc 150 mg
RashSkin and subcutaneous tissue disorders
FatigueGeneral disorders
DizzinessNervous system disorders
VomitingGastrointestinal disorders
HeadacheNervous system disorders
CoughRespiratory, thoracic and mediastinal disorders
PruritusSkin and subcutaneous tissue disorders
Rash pruriticSkin and subcutaneous tissue disorders
NauseaGastrointestinal disorders
PyrexiaGeneral disorders
Lower respiratory tract infectionInfections and infestations
ArthralgiaMusculoskeletal and connective tissue disorders
Musculoskeletal chest painMusculoskeletal and connective tissue disorders

Most-reported serious reactions: Gallbladder polyp.

Data from ClinicalTrials.gov NCT02653625 adverse events section.

Sponsor's own description

This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. CCL5/CCR5 axis in human diseases and related treatments.
    Zeng Z, Lan T, Wei Y, Wei X. · · 2022 · cited 254× · PMID 34514075 · DOI 10.1016/j.gendis.2021.08.004
  2. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
    Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, et al · · 2018 · cited 146× · PMID 29802947 · DOI 10.1016/j.jhep.2018.05.018
  3. Novel therapeutic targets for cholestatic and fatty liver disease.
    Trauner M, Fuchs CD. · · 2022 · cited 141× · PMID 34615727 · DOI 10.1136/gutjnl-2021-324305
  4. Role of chemokine systems in cancer and inflammatory diseases.
    Li H, Wu M, Zhao X. · · 2022 · cited 85× · PMID 35702353 · DOI 10.1002/mco2.147
  5. Review: Pathogenesis of cholestatic liver diseases.
    Yokoda RT, Rodriguez EA. · · 2020 · cited 45× · PMID 32952871 · DOI 10.4254/wjh.v12.i8.423
  6. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
    Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, et al · · 2021 · cited 35× · PMID 33681680 · DOI 10.1002/hep4.1619
  7. Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.
    Yumimoto K, Sugiyama S, Mimori K, Nakayama KI. · · 2019 · cited 35× · PMID 31111571 · DOI 10.1111/cas.14075
  8. Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.
    Tabibian JH, Ali AH, Lindor KD. · · 2018 · cited 34× · PMID 29991937

Verify or expand the search:

Other trials of Cenicriviroc 150 mg

Trials testing the same drug.

Other recruiting trials for Primary Sclerosing Cholangitis

Currently open trials in the same condition.

Other Tobira Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02653625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing